Why This Matters: As global markets adjust their drug policies, Canada faces growing competition for pharmaceutical investment and innovation. Understanding how these global drug policies interact with Canada’s domestic health system is critical to protecting Canada’s health future.
This article outlines how a new U.S. policy, designed to align American drug prices with lower prices in comparable countries, is influencing global drug strategies. As the world’s largest pharmaceutical market, pricing changes in the U.S. have a ripple effect abroad, affecting how companies approach product launches, supply decisions, and investment in medium-size markets like Canada. Understanding these changes is essential to protecting Canada’s health innovation ecosystem and patient access to medical breakthroughs and cutting-edge treatments. For too long, Canada has undervalued and underinvested in pharmaceutical innovation, and global changes are making it increasingly clear that countries that fail to create competitive policy environments risk falling further behind in research, investment, and timely access to new medicines. Read more about this issue here.